News

   

Ori Biotech announces a $9.4M seed round to advance innovation in Cell and Gene Therapy manufacturing

Syndicate includes leading UK investors Amadeus Capital Partners,…

Optimum Strategic Communications Expands Team with Appointment of Shabnam Bashir

08 January 2020, London, UK: Optimum Strategic Communications…

Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations

LONDON, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:…

Edinburgh Molecular Imaging Closes Financing

To accelerate development of molecular targeted systemic radiotherapy…

Forendo Pharma signs important License and Collaboration Deal with Leading Pharma Company

Forendo Pharma, a clinical stage drug development company focusing…

STORM Therapeutics’ collaborator awarded ASH–BSH Abstract Achievement Award at the 61st ASH Annual Meeting & Exposition

09 December 2019, Cambridge, UK: STORM Therapeutics, the biotechnology…

ImaginAb Initiates Phase II Clinical Trial at Penn Medicine

LOS ANGELES, Dec. 9, 2019 /PRNewswire/ -- ImaginAb Inc., a clinical-stage…

IXICO to Present Abstracts at Upcoming Clinical Trials on Alzheimer’s Disease Congress

IXICO plc (AIM: IXI), the AI data analytics company delivering…

Novo Seeds expands company formation activities at BiOrigin with seasoned entrepreneurs

Date: November 26, 2019 Location: Copenhagen Martin…

IXICO Notice of Results

IXICO plc (AIM: IXI), the AI data analytics company delivering…

Azeria Therapeutics announces £32.0 million series B financing

Syncona leads £32.0 million Series B financing of Azeria…

Castor Establishes Advisory Board of Industry Leaders to Maximize the Impact of its Clinical Data Platform

Industry veterans including Craig Lipset will support Castor’s…

Theragnostics strengthens leadership team with two key appointments

Chris Sterling appointed as Non-Executive Director & Radiopharmaceutical…

Calliditas Interim Report Q3, 2019

Positive Regulatory Outcome – Enhanced study design “This…

F2G Receives US FDA Breakthrough Therapy Designation for Olorofim

In Phase 2b development for the treatment of life-threatening…

Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor

CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov.…

IXICO to Present Abstracts at Upcoming Huntington’s Disease and Ataxia Conferences

IXICO plc (AIM: IXI), the AI data analytics company delivering…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.